Optimising cardioprotection during myocardial ischaemia: Targeting potential intracellular pathways with glucagon-like peptide-1

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Clarke, Sophie J ^a   McCormick, Liam M ^a   Dutka, David P ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cardioprotection; Diabetes; GLP 1; Glucagon like peptide 1; Incretin; Ischaemia; Ischaemia reperfusion; Myocardial infarction; Myocardial metabolism; Percutaneous coronary intervention

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE;

CYTOLOGY; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART PROTECTION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOTONIC AGENTS; DRUG DELIVERY SYSTEMS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INTRACELLULAR FLUID; MYOCARDIAL ISCHEMIA; SIGNAL TRANSDUCTION;

EID: 84892385757     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-13-12     Document Type: Review

References (98)

1. Nagendran J, Oudit GY, Bakal JA, Light PE, Dyck JR, McAlister FA. Are users of sulfonylureas at the time of an acute coronary syndrome at risk of poorer outcomes?. Diabetes Obes Metab 2013, 15:1022-1028. 10.1111/dom.12126, 23668425.
2. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234. 10.1056/NEJM199807233390404, 9673301.
3. Frohlich GM, Meier P, White SK, Yellon DM, Hausenloy DJ. Myocardial reperfusion injury: looking beyond primary PCI. Eur Heart J 2013, 32(23):1714-1722.
4. Hausenloy DJ, Botker HE, Condorelli G, Ferdinandy P, Garcia-Dorado D, Heusch G, Lecour S, van Laake LW, Madonna R, Ruiz-Meana M, et al. Translating cardioprotection for patient benefit: position paper from the working group of cellular biology of the heart of the european society of cardiology. Cardiovasc Res 2013, 98(1):7-27. 10.1093/cvr/cvt004, 23334258.
5. Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest 2013, 123:92-100. 10.1172/JCI62874, 3533275, 23281415.
6. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, Vinten-Johansen J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003, 285:H579-H588.
7. Taegtmeyer H, King LM, Jones BE. Energy substrate metabolism, myocardial ischemia, and targets for pharmacotherapy. Am J Cardiol 1998, 82:54K-60K. 10.1016/S0002-9149(98)00538-4, 9737487.
8. Page E, McCallister LP. Quantitative electron microscopic description of heart muscle cells. Application to normal, hypertrophied and thyroxin-stimulated hearts. Am J Cardiol 1973, 31:172-181. 10.1016/0002-9149(73)91030-8, 4265518.
9. Depre C, Vanoverschelde JLJ, Taegtmeyer H. Glucose for the heart. Circulation 1999, 99:578-588. 10.1161/01.CIR.99.4.578, 9927407.
10. Zaninetti D, Greco-Perotto R, Jeanrenaud B. Heart glucose transport and transporters in rat heart: regulation by insulin, workload and glucose. Diabetologia 1988, 31:108-113. 10.1007/BF00395557, 3282950.
11. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 2007, 59:418-458. 10.1124/pr.107.06002, 18048761.
12. Kloner RA, Nesto RW. Glucose-insulin-potassium for acute myocardial infarction: continuing controversy over cardioprotection. Circulation 2008, 117:2523-2533. 10.1161/CIRCULATIONAHA.107.697979, 18474824.
13. Selker HP, Beshansky JR, Sheehan PR, Massaro JM, Griffith JL, D'Agostino RB, Ruthazer R, Atkins JM, Sayah AJ, Levy MK, et al. Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial. JAMA 2012, 307:1925-1933. 10.1001/jama.2012.426, 22452807.
14. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986, 74:1124-1136. 10.1161/01.CIR.74.5.1124, 3769170.
15. Reimer KA, Murry CE, Yamasawa I, Hill ML, Jennings RB. Four brief periods of myocardial ischemia cause no cumulative ATP loss or necrosis. Am J Physiol 1986, 251:H1306-H1315.
16. Davies WR, Brown AJ, Watson W, McCormick LM, West NE, Dutka DP, Hoole SP. Remote ischemic preconditioning improves outcome at 6 years after elective percutaneous coronary intervention: the CRISP stent trial long-term follow-up. Circ Cardiovasc Interv 2013, 6:246-251. 10.1161/CIRCINTERVENTIONS.112.000184, 23696599.
17. Hoole SP, Dutka DP. Does remote ischemic conditioning salvage left ventricular function after successful primary PCI?. Expert Rev Cardiovasc Ther 2011, 9:563-566. 10.1586/erc.11.30, 21615317.
18. Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: underlying mechanisms and clinical application. Atherosclerosis 2009, 204:334-341. 10.1016/j.atherosclerosis.2008.10.029, 19081095.
19. Lehrke M, Marx N. Cardiovascular effects of incretin based therapies. Diabet Stud 2011, 8:382-391.
20. Schulman D, Latchman DS, Yellon DM. Urocortin protects the heart from reperfusion injury via upregulation of p42/p44 MAPK signaling pathway. Am J Physiol Heart Circ Physiol 2002, 283:H1481-H1488.
21. Hausenloy DJ, Lecour S, Yellon DM. Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin. Antioxid Redox Signal 2011, 14:893-907. 10.1089/ars.2010.3360, 20615076.
22. Hausenloy DJ, Tsang A, Yellon DM. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med 2005, 15:69-75. 10.1016/j.tcm.2005.03.001, 15885573.
23. Hausenloy DJ, Yellon DM. Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res 2006, 70:240-253. 10.1016/j.cardiores.2006.01.017, 16545352.
24. Hausenloy DJ, Ong SB, Yellon DM. The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Res Cardiol 2009, 104:189-202. 10.1007/s00395-009-0010-x, 19242644.
25. Javadov SA, Clarke S, Das M, Griffiths EJ, Lim KH, Halestrap AP. Ischaemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart. J Physiol 2003, 549:513-524. 10.1113/jphysiol.2003.034231, 2342939, 12692185.
26. Clarke SJ, Khaliulin I, Das M, Parker JE, Heesom KJ, Halestrap AP. Inhibition of mitochondrial permeability transition pore opening by ischemic preconditioning is probably mediated by reduction of oxidative stress rather than mitochondrial protein phosphorylation. Circ Res 2008, 102:1082-1090. 10.1161/CIRCRESAHA.107.167072, 2629616, 18356542.
27. Okorie MI, Bhavsar DD, Ridout D, Charakida M, Deanfield JE, Loukogeorgakis SP, MacAllister RJ. Postconditioning protects against human endothelial ischaemia-reperfusion injury via subtype-specific KATP channel activation and is mimicked by inhibition of the mitochondrial permeability transition pore. Eur Heart J 2011, 32:1266-1274. 10.1093/eurheartj/ehr041, 21362704.
28. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005, 54:146-151. 10.2337/diabetes.54.1.146, 15616022.
29. Halestrap AP. Mitochondria and reperfusion injury of the heart-a holey death but not beyond salvation. J Bioenerg Biomembr 2009, 41:113-121. 10.1007/s10863-009-9206-x, 19357938.
30. Heusch G, Boengler K, Schulz R. Inhibition of mitochondrial permeability transition pore opening: the holy grail of cardioprotection. Basic Res Cardiol 2010, 105:151-154. 10.1007/s00395-009-0080-9, 20066536.
31. Bernardi P, Broekemeier KM, Pfeiffer DR. Recent progress on regulation of the mitochondrial permeability transition pore; a cyclosporin-sensitive pore in the inner mitochondrial membrane. J Bioenerg Biomembr 1994, 26:509-517. 10.1007/BF00762735, 7896766.
32. Halestrap AP. Calcium-dependent opening of a non-specific pore in the mitochondrial inner membrane is inhibited at pH values below 7. Implications for the protective effect of low pH against chemical and hypoxic cell damage. Biochem J 1991, 278:715-719. 1151405, 1654889.
33. Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J 1995, 307(Pt 1):93-98. 1136749, 7717999.
34. Halestrap AP. The mitochondrial permeability transition: its molecular mechanism and role in reperfusion injury. Biochem Soc Symp 1999, 66:181-203.
35. Hausenloy D, Duchen MR, Yellon DM. Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc Res 2003, 60:617-625. 10.1016/j.cardiores.2003.09.025, 14659807.
36. Argaud L, Gateau-Roesch O, Muntean D, Chalabreysse L, Loufouat J, Robert D, Ovize M. Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury. J Mol Cell Cardiol 2005, 38:367-374. 10.1016/j.yjmcc.2004.12.001, 15698843.
37. Hausenloy DJ, Yellon DM, Mani-Babu S, Duchen MR. Preconditioning protects by inhibiting the mitochondrial permeability transition. Am J Physiol Heart Circ Physiol 2004, 287:H841-H849. 10.1152/ajpheart.00678.2003, 15072953.
38. Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L'Huillier I, Aupetit JF, Bonnefoy E, Finet G, Andre-Fouet X, Ovize M. Postconditioning the human heart. Circulation 2005, 112:2143-2148. 10.1161/CIRCULATIONAHA.105.558122, 16186417.
39. Argaud L, Gateau-Roesch O, Raisky O, Loufouat J, Robert D, Ovize M. Postconditioning inhibits mitochondrial permeability transition. Circulation 2005, 111:194-197. 10.1161/01.CIR.0000151290.04952.3B, 15642769.
40. Halestrap AP. A pore way to die: the role of mitochondria in reperfusion injury and cardioprotection. Biochem Soc Trans 2010, 38:841-860. 10.1042/BST0380841, 20658967.
41. Waldmeier PC, Feldtrauer JJ, Qian T, Lemasters JJ. Inhibition of the mitochondrial permeability transition by the nonimmunosuppressive cyclosporin derivative NIM811. Mol Pharmacol 2002, 62:22-29. 10.1124/mol.62.1.22, 12065751.
42. Ovize M. Cyclosporine and Prognosis in Acute Myocardial Infarction (MI) Patients (CIRCUS). Book Cyclosporine and Prognosis in Acute Myocardial Infarction (MI) Patients (CIRCUS) (Editor ed.^eds.) 2013, City, http://clinicaltrials.gov/show/NCT01502774.
43. Piot C, Croisille P, Staat P, Thibault H, Riofoul G, Mewton N, Elbelghiti R, Cung TT, Bonnefoy E, Angoulvant D, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction.pdf. NEJM 2008, 359:473-481. 10.1056/NEJMoa071142, 18669426.
44. Garlid KD, Halestrap AP. The mitochondrial K(ATP) channel-fact or fiction?. J Mol Cell Cardiol 2012, 52:578-583. 10.1016/j.yjmcc.2011.12.011, 3617982, 22240339.
45. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012, 33:187-215. 10.1210/er.2011-1052, 3528785, 22323472.
46. Plamboeck A, Holst JJ, Carr RD, Deacon CF. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 2005, 48:1882-1890. 10.1007/s00125-005-1847-7, 16025254.
47. Tomas E, Habener JF. Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis. Trends Endocrinol Metab 2010, 21:59-67. 10.1016/j.tem.2009.11.007, 20018525.
48. Mundil D, Beca S, Cameron-Vendrig A, El-Mounayri O, Momen A, Backx PH, Husain M. Abstract 13657: GLP-1 (28-36) exerts direct cardioprotective effects, activating Pro-survival kinases and soluble adenylyl cyclase. Circulation 2012, 126. A13657.
49. Hoole SP, White PA, Read PA, Heck PM, West NE, O'Sullivan M, Dutka DP. Coronary collaterals provide a constant scaffold effect on the left ventricle and limit ischemic left ventricular dysfunction in humans. J Appl Physiol (1985) 2012, 112:1403-1409. 10.1152/japplphysiol.01304.2011, 3331587, 22323649.
50. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, Stolarski C, Shen YT, Shannon RP. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004, 110:955-961. 10.1161/01.CIR.0000139339.85840.DD, 15313949.
51. Ravassa S, Zudaire A, Carr RD, Diez J. Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes. Am J Physiol Heart Circ Physiol 2011, 300:H1361-H1372. 10.1152/ajpheart.00885.2010, 21278133.
52. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007, 87:1409-1439. 10.1152/physrev.00034.2006, 17928588.
53. Roed SN, Wismann P, Underwood CR, Kulahin N, Iversen H, Cappelen KA, Schaffer L, Lehtonen J, Hecksher-Soerensen J, Secher A, et al. Real-time trafficking and signaling of the glucagon-like peptide-1 receptor. Mol Cell Endocrinol 2013, 382(2):938-949.
54. Vila Petroff MG, Egan JM, Wang X, Sollott SJ. Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ Res 2001, 89:445-452. 10.1161/hh1701.095716, 11532906.
55. Ye Y, Keyes KT, Zhang C, Perez-Polo JR, Lin Y, Birnbaum Y. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol 2010, 298:H1454-H1465. 10.1152/ajpheart.00867.2009, 20207816.
56. Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, Simpson JA, Drucker DJ. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 2013, 19:567-575. 10.1038/nm.3128, 23542788.
57. Birnbaum Y, Castillo AC, Qian J, Ling S, Ye H, Perez-Polo JR, Bajaj M, Ye Y. Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus. Cardiovasc Drugs Ther 2012, 26:445-456. 10.1007/s10557-012-6409-x, 22936458.
58. Sonne DP, Engstrom T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 2008, 146:243-249. 10.1016/j.regpep.2007.10.001, 17976835.
59. Wohlfart P, Linz W, Hubschle T, Linz D, Huber J, Hess S, Crowther D, Werner U, Ruetten H. Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies. J Transl Med 2013, 11:84. 10.1186/1479-5876-11-84, 3637243, 23537041.
60. Hausenloy DJ, Whittington HJ, Wynne AM, Begum SS, Theodorou L, Riksen N, Mocanu MM, Yellon DM. Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner. Cardiovasc Diabetol 2013, 12:154. 10.1186/1475-2840-12-154, 3815626, 24148218.
61. Cai Y, Hu X, Yi B, Zhang T, Wen Z. Glucagon-like peptide-1 receptor agonist protects against hyperglycemia-induced cardiocytes injury by inhibiting high mobility group box 1 expression. Mol Biol Rep 2012, 39:10705-10711. 10.1007/s11033-012-1961-9, 23053967.
62. Hu G, Zhang Y, Jiang H, Hu X. Exendin-4 attenuates myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein expression. Cardiol J 2013, 20:600-604. 10.5603/CJ.2013.0159, 24338536.
63. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117:2340-2350. 10.1161/CIRCULATIONAHA.107.739938, 18427132.
64. Ban K, Kim KH, Cho CK, Sauve M, Diamandis EP, Backx PH, Drucker DJ, Husain M. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology 2010, 151:1520-1531. 10.1210/en.2009-1197, 20172966.
65. Pyke C, Knudsen LB. The glucagon-like peptide-1 receptor-or not?. Endocrinology 2013, 154:4-8. 10.1210/en.2012-2124, 23267050.
66. Chai W, Dong Z, Wang N, Wang W, Tao L, Cao W, Liu Z. Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes 2012, 61:888-896. 10.2337/db11-1073, 3314347, 22357961.
67. Golpon HA, Puechner A, Welte T, Wichert PV, Feddersen CO. Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat. Regul Pept 2001, 102:81-86. 10.1016/S0167-0115(01)00300-7, 11730979.
68. Green BD, Hand KV, Dougan JE, McDonnell BM, Cassidy RS, Grieve DJ. GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys 2008, 478:136-142. 10.1016/j.abb.2008.08.001, 18708025.
69. Richter G, Feddersen O, Wagner U, Barth P, Goke R, Goke B. GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am J Physiol 1993, 265:L374-L381.
70. Nystrom T, Gonon AT, Sjoholm A, Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 2005, 125:173-177. 10.1016/j.regpep.2004.08.024, 15582729.
71. Ozyazgan S, Kutluata N, Afsar S, Ozdas SB, Akkan AG. Effect of glucagon-like peptide-1(7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats. Pharmacology 2005, 74:119-126.
72. Gardiner SM, March JE, Kemp PA, Bennett T. Mesenteric vasoconstriction and hindquarters vasodilatation accompany the pressor actions of exendin-4 in conscious rats. J Pharmacol Exp Ther 2006, 316:852-859.
73. Barragan JM, Eng J, Rodriguez R, Blazquez E. Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am J Physiol 1999, 277:E784-E791.
74. Gejl M, Sondergaard HM, Stecher C, Bibby BM, Moller N, Botker HE, Hansen SB, Gjedde A, Rungby J, Brock B. Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes. J Clin Endocrinol Metab 2012, 97:E1165-E1169. 10.1210/jc.2011-3456, 22544917.
75. Nystrom T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahren B, Sjoholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004, 287:E1209-E1215. 10.1152/ajpendo.00237.2004, 15353407.
76. Ceriello A, Esposito K, Testa R, Bonfigli AR, Marra M, Giugliano D. The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an " endothelial resistance" to glucagon-like peptide 1 in diabetes. Diabetes Care 2011, 34:697-702. 10.2337/dc10-1949, 3041210, 21273492.
77. Basu A, Charkoudian N, Schrage W, Rizza RA, Basu R, Joyner MJ. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab 2007, 293:E1289-E1295. 10.1152/ajpendo.00373.2007, 17711996.
78. Valensi P, Chiheb S, Fysekidis M. Insulin- and glucagon-like peptide-1-induced changes in heart rate and vagosympathetic activity: why they matter. Diabetologia 2013, 56:1196-1200. 10.1007/s00125-013-2909-x, 23584434.
79. Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 2013, 3:e001986. doi:10.1136/bmjopen-2012-001986, 3563145, 23355666.
80. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Sondergaard RE, Davies M, Group L-D-S Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010, 375:1447-1456. 10.1016/S0140-6736(10)60307-8, 20417856, Group L-D-S.
81. Mendis B, Simpson E, MacDonald I, Mansell P. Investigation of the haemodynamic effects of exenatide in healthy male subjects. Br J Clin Pharmacol 2012, 74:437-444. 10.1111/j.1365-2125.2012.04214.x, 3477345, 22320349.
82. Read PA, Khan FZ, Dutka DP. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart 2012, 98:408-413. 10.1136/hrt.2010.219345, 21561896.
83. Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging 2010, 3:195-201. 10.1161/CIRCIMAGING.109.899377, 20075143.
84. McCormick LM, Kydd AC, Ring LS, Clarke SJ, Dutka DP. Glucagon-like peptide-1 improves the myocardial response to demand ischemia during hyperglycemia in patients with type 2 diabetes mellitus and coronary artery disease. Circulation 2013, 128:A17348.
85. Read PA, Hoole SP, White PA, Khan FZ, O'Sullivan M, West NE, Dutka DP. A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ Cardiovasc Interv 2011, 4:266-272. 10.1161/CIRCINTERVENTIONS.110.960476, 21586690.
86. McCormick LM, Hoole SP, White PA, Read PA, Axell R, Clarke SJ, O'Sullivan M, West NEJ, Dutka DP. Pre-treatment with glucagon-like peptide-1 protects against supply ischemic left ventricular dysfunction - insights from conductance catheter assessment during elective PCI. Circulation 2013, 128:A17497.
87. Lonborg J, Vejlstrup N, Kelbaek H, Botker HE, Kim WY, Mathiasen AB, Jorgensen E, Helqvist S, Saunamaki K, Clemmensen P, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012, 33:1491-1499. 10.1093/eurheartj/ehr309, 21920963.
88. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109:962-965. 10.1161/01.CIR.0000120505.91348.58, 14981009.
89. Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: united at reperfusion. Pharmacol Ther 2007, 116:173-191. 10.1016/j.pharmthera.2007.06.005, 17681609.
90. Yellon DM, Hausenloy DJ. Realizing the clinical potential of ischemic preconditioning and postconditioning. Nat Clin Pract Cardiovasc Med 2005, 2:568-575. 10.1038/ncpcardio0346, 16258568.
91. Monami M, Ahren B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013, 15:112-120. 10.1111/dom.12000, 22925682.
92. Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011, 27(Suppl 3):57-64.
93. Engel SS, Golm GT, Shapiro D, Davies MJ, Kaufman KD, Goldstein BJ. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol 2013, 12:3. 10.1186/1475-2840-12-3, 3585887, 23286208.
94. Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol 2012, 11:3. 10.1186/1475-2840-11-3, 3286367, 22234149.
95. Best JH, Hoogwerf BJ, Herman WH, Pelletier EM, Smith DB, Wenten M, Hussein MA. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 2011, 34:90-95. 10.2337/dc10-1393, 3005487, 20929995.
96. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013, 369:1317-1326. 10.1056/NEJMoa1307684, 23992601.
97. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013, 369:1327-1335. 10.1056/NEJMoa1305889, 23992602.
98. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009, 339:b2700. 10.1136/bmj.b2700, 2714672, 19622552.